Inspire Medical Systems, Inc. (INSP) Quick Ratio
- Quick ratio · latest quarter: Value 5.96×; Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | 5.96× | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. $424.02M ÷ $71.18M ≈ 5.96× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | 424.02M USD | Cash and Cash Equivalents, at Carrying Value · Debt Securities, Available-for-sale, Current · Accounts Receivable, after Allowance for Credit Loss, Current |
| Current obligations | 71.18M USD | Liabilities, Current |
| Cash and equivalents | 127.76M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 192.92M USD | Debt Securities, Available-for-sale, Current |
| Customer receivables | 103.34M USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory · excluded from quick assets | 170.45M USD | Inventory, Net |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $424.02M | $71.18M | $127.76M | $192.92M | $103.34M | $170.45M | 5.96× |
| 2026-03-31 | $388.92M | $89.42M | $98.93M | $184.90M | $105.09M | $166.24M | 4.35× |
| 2025-12-31 | $427.96M | $96.06M | $104.81M | $203.46M | $119.69M | $145.29M | 4.46× |
| 2025-09-30 | $430.58M | $110.84M | $112.84M | $209.75M | $107.99M | $141.78M | 3.88× |
| 2025-06-30 | $438.58M | $93.36M | $106.93M | $193.97M | $137.69M | $121.63M | 4.70× |
| 2025-03-31 | $461.82M | $63.47M | $53.88M | $315.31M | $92.63M | $99.73M | 7.28× |
| 2024-12-31 | $538.61M | $88.50M | $150.15M | $295.40M | $93.07M | $80.12M | 6.09× |
| 2024-09-30 | $500.73M | $74.26M | $147.51M | $263.48M | $89.74M | $67.43M | 6.74× |
| 2024-06-30 | $519.38M | $65.66M | $188.03M | $251.63M | $79.72M | $59.02M | 7.91× |
| 2024-03-31 | $513.69M | $72.17M | $175.42M | $265.94M | $72.33M | $48.97M | 7.12× |
| 2023-12-31 | $550.26M | $78.11M | $185.54M | $274.84M | $89.88M | $33.88M | 7.05× |
| 2023-09-30 | $535.67M | $70.00M | $329.90M | $134.32M | $71.46M | $26.11M | 7.65× |
| 2023-06-30 | $530.55M | $66.69M | $467.05M | $0.00 | $63.50M | $20.84M | 7.96× |
| 2023-03-31 | $511.82M | $59.87M | $442.13M | $9.93M | $59.77M | $15.66M | 8.55× |
| 2022-12-31 | $512.64M | $61.19M | $441.59M | $9.82M | $61.23M | $11.89M | 8.38× |
| 2022-09-30 | (m) | $49.29M | $417.81M | (m) | $48.50M | $15.15M | (m) |
| 2022-06-30 | (m) | $46.85M | $186.57M | (m) | $40.38M | $21.86M | (m) |
| 2022-03-31 | (m) | $43.17M | $203.29M | (m) | $34.54M | $22.20M | (m) |
| 2021-12-31 | (m) | $41.31M | $214.47M | (m) | $34.18M | $17.23M | (m) |
| 2021-09-30 | (m) | $33.59M | $210.20M | (m) | $26.68M | $15.57M | (m) |
| 2021-06-30 | (m) | $24.35M | $176.54M | (m) | $24.91M | $13.30M | (m) |
| 2021-03-31 | (m) | $19.42M | $182.35M | (m) | $21.65M | $11.38M | (m) |
| 2020-12-31 | (m) | $20.73M | $190.52M | (m) | $25.06M | $8.48M | (m) |
| 2020-09-30 | (m) | $18.20M | $178.71M | (m) | $21.10M | $8.97M | (m) |
| 2020-06-30 | (m) | $13.04M | $211.24M | (m) | $10.23M | $9.97M | (m) |
| 2020-03-31 | (m) | $13.72M | $76.12M | (m) | $11.03M | $7.25M | (m) |
| 2019-12-31 | (m) | $16.86M | $22.86M | (m) | $13.13M | $5.83M | (m) |
| 2019-09-30 | (m) | $12.70M | $48.04M | (m) | $10.98M | $4.67M | (m) |
| 2019-06-30 | (m) | $8.66M | $51.27M | (m) | $9.46M | $3.56M | (m) |
| 2019-03-31 | (m) | $7.83M | $101.94M | (m) | $7.04M | $3.11M | (m) |
| 2019-01-01 | (m) | $11.17M | (m) | (m) | (m) | (m) | (m) |
| 2018-12-31 | (m) | $11.15M | $97.29M | (m) | $6.67M | $2.67M | (m) |
| 2018-09-30 | (m) | $7.59M | $26.31M | (m) | $5.41M | $3.08M | (m) |
| 2018-06-30 | (m) | $9.34M | $121.85M | (m) | $4.49M | $3.55M | (m) |
| 2018-03-31 | (m) | $7.92M | $11.15M | (m) | $3.46M | $3.39M | (m) |
| 2017-12-31 | (m) | $7.15M | $8.96M | (m) | $3.86M | $3.67M | (m) |
| 2017-09-30 | (m) | (m) | $14.54M | (m) | (m) | (m) | (m) |
| 2017-06-30 | (m) | (m) | $22.51M | (m) | (m) | (m) | (m) |
| 2017-03-31 | (m) | (m) | $26.55M | (m) | (m) | (m) | (m) |
| 2016-12-31 | (m) | (m) | $6.68M | (m) | (m) | (m) | (m) |
| 2015-12-31 | (m) | (m) | $12.13M | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NovoCure Ltd (NVCR) | $1.886B | -11.87 | |
| LEMAITRE VASCULAR INC (LMAT) | United States | $1.848B | 33.37 |
| UFP TECHNOLOGIES INC (UFPT) | United States | $2.308B | 28.37 |
| KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) | United States | $1.535B | -9.02 |
| Alphatec Holdings, Inc. (ATEC) | United States | $1.531B | -12.14 |
| INTEGRA LIFESCIENCES HOLDINGS CORP (IART) | United States | $1.234B | -193.02 |
| ARTIVION, INC. (AORT) | United States | $1.123B | -345.09 |
| IRADIMED CORP (IRMD) | United States | $1.089B | 52.92 |
| TANDEM DIABETES CARE INC (TNDM) | United States | $1.059B | -16.57 |
| PROCEPT BioRobotics Corp (PRCT) | United States | $1.001B | -11.77 |